Leap Therapeutics (LPTX) Competitors $2.59 -0.11 (-4.07%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends LPTX vs. TNXP, PRPH, MRSN, ETON, PSTX, AVIR, URGN, LFCR, NGNE, and ATYRShould you be buying Leap Therapeutics stock or one of its competitors? The main competitors of Leap Therapeutics include Tonix Pharmaceuticals (TNXP), ProPhase Labs (PRPH), Mersana Therapeutics (MRSN), Eton Pharmaceuticals (ETON), Poseida Therapeutics (PSTX), Atea Pharmaceuticals (AVIR), UroGen Pharma (URGN), Lifecore Biomedical (LFCR), Neurogene (NGNE), and Atyr PHARMA (ATYR). These companies are all part of the "pharmaceutical products" industry. Leap Therapeutics vs. Tonix Pharmaceuticals ProPhase Labs Mersana Therapeutics Eton Pharmaceuticals Poseida Therapeutics Atea Pharmaceuticals UroGen Pharma Lifecore Biomedical Neurogene Atyr PHARMA Tonix Pharmaceuticals (NASDAQ:TNXP) and Leap Therapeutics (NASDAQ:LPTX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, community ranking, dividends, risk, media sentiment, institutional ownership, earnings, profitability and analyst recommendations. Which has more risk and volatility, TNXP or LPTX? Tonix Pharmaceuticals has a beta of 2.06, meaning that its stock price is 106% more volatile than the S&P 500. Comparatively, Leap Therapeutics has a beta of 0.22, meaning that its stock price is 78% less volatile than the S&P 500. Do institutionals & insiders have more ownership in TNXP or LPTX? 82.3% of Tonix Pharmaceuticals shares are held by institutional investors. Comparatively, 30.5% of Leap Therapeutics shares are held by institutional investors. 0.0% of Tonix Pharmaceuticals shares are held by company insiders. Comparatively, 5.4% of Leap Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Do analysts recommend TNXP or LPTX? Tonix Pharmaceuticals presently has a consensus target price of $53.50, suggesting a potential upside of 28,057.89%. Leap Therapeutics has a consensus target price of $7.50, suggesting a potential upside of 189.58%. Given Tonix Pharmaceuticals' higher probable upside, equities analysts plainly believe Tonix Pharmaceuticals is more favorable than Leap Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tonix Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Leap Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer TNXP or LPTX? Tonix Pharmaceuticals received 47 more outperform votes than Leap Therapeutics when rated by MarketBeat users. However, 68.94% of users gave Leap Therapeutics an outperform vote while only 61.82% of users gave Tonix Pharmaceuticals an outperform vote. CompanyUnderperformOutperformTonix PharmaceuticalsOutperform Votes34061.82% Underperform Votes21038.18% Leap TherapeuticsOutperform Votes29368.94% Underperform Votes13231.06% Does the media prefer TNXP or LPTX? In the previous week, Leap Therapeutics had 1 more articles in the media than Tonix Pharmaceuticals. MarketBeat recorded 6 mentions for Leap Therapeutics and 5 mentions for Tonix Pharmaceuticals. Leap Therapeutics' average media sentiment score of 1.24 beat Tonix Pharmaceuticals' score of 0.28 indicating that Leap Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tonix Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Leap Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is TNXP or LPTX more profitable? Leap Therapeutics has a net margin of 0.00% compared to Tonix Pharmaceuticals' net margin of -1,197.86%. Leap Therapeutics' return on equity of -116.24% beat Tonix Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Tonix Pharmaceuticals-1,197.86% -163.95% -118.88% Leap Therapeutics N/A -116.24%-93.18% Which has preferable earnings & valuation, TNXP or LPTX? Leap Therapeutics has lower revenue, but higher earnings than Tonix Pharmaceuticals. Leap Therapeutics is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTonix Pharmaceuticals$7.77M3.36-$116.66M-$52.740.00Leap Therapeutics$1.50M44.20-$81.41M-$1.93-1.34 SummaryLeap Therapeutics beats Tonix Pharmaceuticals on 11 of the 17 factors compared between the two stocks. Ad Darwin2025 AI Stock Picks: 2 Hidden Gems Under $10/ShareThe AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.👉[Click here to get your FREE report delivered instantly!] Get Leap Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LPTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LPTX vs. The Competition Export to ExcelMetricLeap TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$69.12M$6.48B$5.07B$8.89BDividend YieldN/A8.11%4.99%4.07%P/E Ratio-1.344.4283.5712.93Price / Sales44.20375.031,220.3088.33Price / CashN/A52.5939.4636.25Price / Book1.3610.126.936.25Net Income-$81.41M$153.61M$119.12M$225.93M7 Day Performance-10.38%-2.00%-1.83%-1.32%1 Month Performance-13.09%-7.47%-3.64%0.60%1 Year Performance6.15%31.80%31.64%26.23% Leap Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LPTXLeap Therapeutics2.3936 of 5 stars$2.59-4.1%$7.50+189.6%+25.1%$69.12M$1.50M-1.3440Positive NewsTNXPTonix Pharmaceuticals2.9676 of 5 stars$0.19+18.8%$53.50+28,057.9%-98.8%$22.33M$7.77M0.00103Analyst ForecastGap UpHigh Trading VolumePRPHProPhase Labs3.242 of 5 stars$0.77+1.3%$11.00+1,337.9%-82.8%$18.14M$44.38M0.00130MRSNMersana Therapeutics4.3672 of 5 stars$2.22flat$6.00+170.3%+38.8%$274.24M$36.85M0.00150Analyst RevisionETONEton Pharmaceuticals2.9126 of 5 stars$10.43-0.7%$13.00+24.6%+202.8%$271.28M$31.64M0.0020Short Interest ↓Analyst RevisionPSTXPoseida Therapeutics4.0406 of 5 stars$2.72-1.8%$15.00+451.5%-0.5%$269.98M$64.70M0.00260AVIRAtea Pharmaceuticals2.7626 of 5 stars$3.16+0.6%$6.88+117.7%+5.0%$265.21M$351.37M0.0070URGNUroGen Pharma3.78 of 5 stars$11.45+2.6%$48.38+322.5%-7.9%$261.74M$82.71M-3.63200LFCRLifecore Biomedical1.5431 of 5 stars$7.48+5.5%$8.00+7.0%+0.7%$261.10M$128.26M93.50690NGNENeurogene2.936 of 5 stars$15.33-11.0%$60.83+296.8%N/A$255.95MN/A0.0090Analyst ForecastAnalyst RevisionNews CoverageATYRAtyr PHARMA2.8572 of 5 stars$2.99-1.6%$19.25+543.8%N/A$255.18M$350,000.00-3.1856 Related Companies and Tools Related Companies Tonix Pharmaceuticals Alternatives ProPhase Labs Alternatives Mersana Therapeutics Alternatives Eton Pharmaceuticals Alternatives Poseida Therapeutics Alternatives Atea Pharmaceuticals Alternatives UroGen Pharma Alternatives Lifecore Biomedical Alternatives Neurogene Alternatives Atyr PHARMA Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:LPTX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Leap Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Leap Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
